1. The two-year risk of developing cardiovascular death, nonfatal myocardial infarction (MI) or stroke was approximately 25% less in patients taking semaglutide compared to placebo. 2. Two-year use of semaglutide linked to significantly lower levels for glycated hemoglobin (HbA1c) levels, weight and systolic blood pressure compared to placebo. Evidence Rating Level: 1 (Excellent)
↧